OraSure Technologies

OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. The OSUR segment offer oral fluid diagnostic products and specimen collection devices. The DNAG segment produces specimen collection kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. The company was founded by Michael J. Gausling in May 2000 in and is headquartered in Bethlehem, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

OraSure Technologies excels in Q4 2022, eyes strategic partnerships for growth

OraSure Technologies showcased robust financial performance, operational efficiency, and strategic partnerships in Q4 2022.
While facing challenges in margin structure and international mix, the company is focused on core growth and cost-saving initiatives.
Opportunities lie in business unit consolidation, product innovation, and strategic partnerships for future growth and profitability.

OraSure Technologies reports record Q1 revenue, focuses on growth

OraSure Technologies delivered strong Q1 results with record revenue and improved margins, driven by IntelliSwab sales. While facing challenges in product diversification and cost management, the company's focus on efficiency and innovation presents growth opportunities. Strategic partnerships and a solid financial position further support its growth trajectory.

OraSure Technologies reports robust Q2 earnings, eyes growth opportunities ahead

OraSure Technologies delivered strong financial performance in Q2 2023, with revenue growth, operating cash flow, and strategic advancements across key business segments.
While facing challenges in margin improvement and revenue forecasting, the company's focus on cost reductions, operational efficiencies, and growth strategies positions it for long-term success.
By leveraging strengths in core business areas, collaborations, and innovation, OraSure is well-positioned to capitalize on opportunities for accelerated growth and market expansion.

OraSure Technologies excels in Q3 with revenue growth and strategic milestones

OraSure Technologies demonstrated strong financial performance and operational efficiency in Q3 2023, with notable revenue growth and cash flow generation.
While facing challenges in margin moderation and operating expenses, the company's strategic focus on innovation and partnerships presents growth opportunities.
Overall, OraSure's successful milestones, revenue diversification, and cost management efforts position it for continued growth and market leadership.

OraSure Technologies posts strong Q4 results amidst market challenges

OraSure Technologies demonstrated robust financial performance in Q4 2023, driven by revenue diversification and strategic cost-saving initiatives.
While facing challenges in muted core revenue growth for Q1 2024, the company remains confident in its long-term growth prospects.
Strategic partnerships and investments present opportunities for revenue expansion and market penetration in key segments.

OraSure Technologies surpasses Q1 revenue targets, eyes operational breakeven

OraSure Technologies delivered strong financial performance in Q1, exceeding revenue guidance and showcasing core revenue strength.
While facing challenges in business transitions and cost management, the company's strategic focus on efficiency and growth presents opportunities.
With a solid cash position, key partnerships, and a clear roadmap to breakeven in operating cash flow, OraSure is poised for future success.

OraSure Technologies reports robust Q2 results and eyes global expansion

OraSure Technologies delivered strong Q2 financial results with revenue near guidance ranges and operational improvements.
The company faces challenges in cost restructuring and gross margin outlook but sees growth opportunities in new products and partnerships.
International revenue growth, strategic partnerships, and product extensions position OraSure for future success and market expansion.

OraSure Technologies reports stable Q3 performance and eyes growth

OraSure Technologies navigated Q3 with stable financial performance, focusing on core revenue growth and strategic business realignment.
The company's emphasis on innovation, new market entry, and financial strength positions it well for future growth and market expansion.
While challenges like revenue decline and business transitions exist, OraSure Technologies is proactively addressing them to capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. The OSUR segment offers oral fluid diagnostic products and specimen collection devices. The DNAG segment produces specimen collection kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. The company was founded by Michael J. Gausling in 2000 in and is headquartered in Bethlehem, PA.

BETHLEHEM, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that the company is scheduled to participate in the following investor conference:

OraSure to Participate in Upcoming Investor Conference

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is OraSure Technologies (OSUR) a Great Value Stock Right Now?

OraSure Technologies, Inc. (OSUR) Q3 2024 Earnings Call Transcript

OraSure Technologies (OSUR) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.27 per share a year ago.

OraSure Technologies (OSUR) Reports Q3 Loss, Tops Revenue Estimates

Q3 GAAP EPS of $(0.06) ; Q3 Non-GAAP EPS of $(0.01) OraQuick® HCV Self-test receives initial orders following receipt of WHO pre-qualification status Expanding Sample Management applications into blood proteomics Exiting Risk Assessment testing business to focus on markets with attractive growth opportunities BETHLEHEM, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended September 30, 2024.

OraSure Reports Q3 '24 Revenue of $39.9 Million

OraSure Technologies Inc. is a health and wellness company specializing in "easy to use" diagnostic and specimen collection products. OraSure has a strong balance sheet and is trading below its net current asset value (NCAV). At the same time, OraSure has a stable operational history with consistent normalized cash flow margins.

OraSure: An NCAV Diamond In The COVID Rough

BETHLEHEM, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering third quarter 2024 financial results and certain business developments for 5 p.m. ET on November 6, 2024.

OraSure to Announce Third Quarter 2024 Financial Results and Host Earnings Call on November 6th

On September 30, 2024, Neuberger Berman Group LLC, a prominent investment firm, made a significant addition to its investment portfolio by acquiring 3,927,692 shares of OraSure Technologies Inc (OSUR, Financial). This transaction, executed at a price of $4.27 per share, marks a notable increase in the firm's holdings in the medical devices sector.

Neuberger Berman Group LLC Expands Stake in OraSure Technologies Inc

BETHLEHEM, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions today announced the election of Jack Kenny to its Board of Directors, effective September 9, 2024. With the addition of Mr. Kenny, OraSure's Board of Directors currently has seven members.

OraSure Technologies Elects Jack Kenny to the Board of Directors

OraSure Technologies Inc (NASDAQ:OSUR ) Q2 2024 Results Conference Call August 6, 2024 5:00 PM ET Company Participants Jason Plagman - Vice President-Investor Relations Carrie Eglinton Manner - President and Chief Executive Officer Ken McGrath - Chief Financial Officer Conference Call Participants Casey Woodring - JPMorgan Andrew Cooper - Raymond Jones Operator Good day, and thank you for standing by. Welcome to the OraSure Technologies Incorporated 2024 Second Quarter Earnings Conference Call.

OraSure Technologies Inc (OSUR) Q2 2024 Earnings Call Transcript

OraSure Technologies (OSUR) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to loss of $0.07 per share a year ago.

OraSure Technologies (OSUR) Tops Q2 Earnings and Revenue Estimates

BETHLEHEM, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering second quarter 2024 financial results and certain business developments for 5 p.m. ET on August 6, 2024.

OraSure to Announce Second Quarter 2024 Financial Results and Host Earnings Call on August 6th

BETHLEHEM, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions today announced its support of HIV testing initiatives taking place across the nation in recognition of National HIV Testing Day, held each year on June 27th. These testing initiatives will help encourage thousands of people across the U.S. to get tested for HIV.

OraSure Technologies Supports National HIV Testing Day

OraSure Technologies (OSUR) came out with quarterly earnings of $0.04 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.37 per share a year ago.

OraSure Technologies (OSUR) Q1 Earnings Meet Estimates

BETHLEHEM, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2024 financial results and certain business developments for 4:45 p.m. ET on Wednesday, May 8, 2024.

OraSure to Announce First Quarter 2024 Financial Results and Host Earnings Call on May 8th

Acacia Research

WisdomTree Inc

Penny stocks are those that trade under $5. We'll call stocks that trade between $5 and $10 near-penny stocks.

Wall Street Favorites: 3 Under-$10 Stocks With Strong Buy Ratings for April 2024

SPRINGDALE, Ark.--(BUSINESS WIRE)--NOWDiagnostics (NOWDx), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostics tests and first-in-class technology and platforms, today announced the appointment of Dr. Stephen S. Tang, Ph.D., MBA, as the chairman of the company's board of directors. Dr. Tang is a longtime veteran of the medical diagnostic industry. He led OraSure Technologies, Inc. (NASDAQ: OSUR), a pioneer and global leader in rapid at-home tests for HIV and COVID-19, for.

NOWDiagnostics Welcomes Dr. Stephen S. Tang as Chairman of the Board

OraSure Technologies, Inc. (OSUR) Q4 2023 Earnings Call Transcript

Q4 GAAP EPS of $0.27 ; Q4 Non-GAAP EPS of $0.22 Grew cash balance to $290.4 million as of December 31, 2023 E nters U.S. Syphilis testing market via strategic distribution agreement with Diagnostics Direct BETHLEHEM, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, sample management solutions, and microbiome laboratory and analytical services, today announced its financial results for the three months ended December 31, 2023.

OraSure Reports Q4 ‘23 Revenue of $75.9 Million

BETHLEHEM, Pa., Feb. 13, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering fourth quarter 2023 financial results and certain business developments for 5 p.m. ET on Tuesday, Feb. 27, 2024.

OraSure to Announce Fourth Quarter 2023 Financial Results and Host Earnings Call on February 27th

Kinross Gold

Nordic American Tankers

Investors seeking strong buy stocks under $10 offering a potential future of large returns can be difficult. Inexpensive companies tend to have a small market cap and are typically riskier investments compared to stocks that trade for a higher market cap.

3 Strong Buy Stocks Under $10: January 2024

The relationship expands OraSure's innovation pipeline with access to a broad portfolio of key Sapphiros products in development.

OraSure Technologies, Inc. Secures Strategic Distribution Rights and Invests in Sapphiros, a Next-Generation Consumer Diagnostics Company

After reaching an important support level, OraSure Technologies, Inc. (OSUR) could be a good stock pick from a technical perspective. OSUR recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

After Golden Cross, OraSure Technologies (OSUR)'s Technical Outlook is Bright

BETHLEHEM, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced the company is scheduled to participate in the following investor conferences:

OraSure to Participate in Upcoming Investor Conferences

Alkermes

Amphastar Pharma

Ginkgo Bioworks Holdings

DaVita

Jazz Pharmaceuticals

United Therapeutics

If you're a fan of the hit TV show Shark Tank, you've probably come across the intriguing term “unicorn” companies. Indeed, these fantastical entities are not only confined to the realm of imagination.

News for OraSure Technologies Stock (OSUR)